Literature DB >> 7984782

Glucocorticoid-induced osteoporosis.

B P Lukert1, L G Raisz.   

Abstract

Glucocorticoids are important in the management of rheumatic diseases. Bone loss is one of the most devastating side effects of glucocorticoids because they inhibit calcium transport, cause secondary hyperparathyroidism, hypogonadism, and impairment of osteoblast function. Efforts to control these side effects minimize bone loss.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7984782

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN： 0889-857X            Impact factor:   2.670


  17 in total

Review 1.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

2.  Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study.

Authors:  J Jahnsen; J A Falch; E Aadland; P Mowinckel
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

3.  Longitudinal study of bone mineral density in patients with Crohn's disease.

Authors:  D J de Jong; L Mannaerts; L G M van Rossum; F H M Corstens; A H J Naber
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

4.  Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Authors:  A Balasubramanian; S W Wade; R A Adler; C J F Lin; M Maricic; C D O'Malley; K Saag; J R Curtis
Journal:  Osteoporos Int       Date:  2016-06-08       Impact factor: 4.507

5.  Bilateral spontaneous inter-trochanteric fractures of proximal femurs.

Authors:  Aysha Rajeev
Journal:  Int J Surg Case Rep       Date:  2014-03-12

6.  Inflammatory bowel disease and predisposition to osteopenia.

Authors:  F J Cowan; J T Warner; F D Dunstan; W D Evans; J W Gregory; H R Jenkins
Journal:  Arch Dis Child       Date:  1997-04       Impact factor: 3.791

7.  Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease.

Authors:  Subrata Ghosh; Brian Bressler; Jill Petkau; Roopal B Thakkar; Song Wang; Martha Skup; Jingdong Chao; Remo Panaccione; Stefan Schreiber
Journal:  Dig Dis Sci       Date:  2019-01-19       Impact factor: 3.199

8.  A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.

Authors:  P Pitt; F Li; P Todd; D Webber; S Pack; C Moniz
Journal:  Thorax       Date:  1998-05       Impact factor: 9.139

9.  Cyclosporin A elicits dose-dependent biphasic effects on osteoblast differentiation and bone formation.

Authors:  Hyeonju Yeo; Lauren H Beck; Jay M McDonald; Majd Zayzafoon
Journal:  Bone       Date:  2007-02-24       Impact factor: 4.398

10.  Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma.

Authors:  T-T Dam; S Harrison; H A Fink; J Ramsdell; E Barrett-Connor
Journal:  Osteoporos Int       Date:  2009-10-09       Impact factor: 4.507
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.